Contact Us

GENTAUR Europe

 GENTAUR Europe BVBA
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.  

Gentaur Bulgaria

 GENTAUR BULGARIA
53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280 
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR France
    Gentaur Germany

      GmbH Marienbongard 20
    52062 Aachen Deutschland
    Tel (+49) 0241 56 00 99 68 
    Fax (+49) 0241 56 00 47 88 
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it.

     

    Gentaur London

     GENTAUR Ltd. 
    Howard Frank Turnberry House 
    1404-1410 High Road 
    Whetstone London N20 9BH 
    Tel 020 3393 8531 
    Fax 020 8445 9411
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Poland

     GENTAUR Poland Sp. z o.o. 

    ul. Grunwaldzka 88/A m.2

    81-771 Sopot, Poland
    Tel  058 710 33 44
    Fax 058 710 33 48 
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Nederland

     GENTAUR Nederland BV
    Kuiper 1 
    5521 DG Eersel Nederland
    Tel 0208-080893 
    Fax 0497-517897
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Italy

     GENTAUR SRL IVA IT03841300167

    Piazza Giacomo Matteotti, 6, 24122 Bergamo
    Tel 02 36 00 65 93 
    Fax 02 36 00 65 94
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Spain

     GENTAUR Spain
    Tel 0911876558
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Genprice USA
    Gentaur Serbia

    serbiaSerbia, Macedonia FlagMacedonia, 

    montenegro-flagMontenegro, croatiaCroatia: 
    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Romania

    romGENTAUR Romania

    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Greece

    grGENTAUR Greece 

    Tel 00302111768494 
    Fax 0032 16 50 90 45

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Other countries

    Other countries
    Luxembourg +35220880274
    Schweiz Züri +41435006251
    Danmark +4569918806
    Österreich +43720880899
    Ceská republika Praha +420246019719
    Ireland Dublin +35316526556
    Norge Oslo +4721031366
    Finland Helsset +358942419041
    Sverige Stockholm +46852503438
    Magyarország Budapest +3619980547

    seal-in-search-symantec

     

     


    Friday, 11 January 2013 11:03

    An Innovative Evolution in Influenza Vaccine Manufacturing

    Rate this item
    (1 Vote)

    Millions of lives have been changed over the past fourthy years because of advances in medical technology. From stem-cell research to reengineering the way we take our daily medications, all these developments have brought health care into the 21st century. There has been a vast disconnect between these improvements and the manufacturing processes used to provide influenza vaccines to the public.

    Shockingly, the method used to produce the influenza vaccine has not been significantly transformed since 1931, when vaccines used for preventive care were first introduced to the public.

    Influenza causes between 3,000 and 48,000 deaths and 190,000 hospitalizations in any given season, so it is critical to utilize the most effective production methods to create influenza vaccines to protect our communities. Until recently, all influenza vaccines available in the U.S. were produced by growing and harvesting the virus in chicken eggs. During the time this method has been successful, millions of eggs are needed to produce enough vaccine for our communities each year, requiring production to begin many months in advance. Once the virus strains are selected for the upcoming influenza season by the WHO (World Health Organization), and companies begin manufacturing the vaccine, it can take anywhere between 6 and 9 months to make the vaccine available to physicians or pharmacists.

    The egg-based manufacturing process has been working for us to date; however, there is a new process that raises the bar in influenza vaccine manufacturing, is less time-consuming and brings the manufacturing process into the digital age.

    Cell-culture technology is the latest production technique for influenza vaccine manufacturing, which involves growing the virus in cells from mammals, rather than chicken eggs. This method offers advantages over the conventional egg-based process:

    • Since no eggs need to be collected, vaccines can be produced and available to the public quicker, which is critical in case of a flu pandemic.

    • The process does not use any preservatives or antibiotics during production.

    Cell-culture technology has been successfully used to manufacture many other vaccines, including those distributed during the H1N1 pandemic, as well as vaccines for polio, rubella and hepatitis A. This technology also has been tried and tested in other countries, which have already approved and use cell-based influenza vaccines abroad. Recently, the FDA gave its stamp of approval to use the technology in influenza vaccines available in the U.S., with an approval of a cell-based seasonal influenza vaccine.

    It is important that such a fundamental vaccine that every American ages 6 months and older is advised to receive each year is available using the most cutting-edge technology. I am excited to see how this major advancement will help start a new chapter in the evolution of influenza prevention.

    Read 433 times